Report
Dominic Rose ...
  • Naresh Chouhan
EUR 4631.50 For Business Accounts Only

Novo Nordisk - Cut to Sell - The Wood for The Trees (TP DKK 460)

Whilst the Wegovy scrips are scrutinised on literally a daily basis, US Ozempic softness seems to have been ignored despite Ozempic being 2x bigger than Wegovy in terms of global sales. New analysis makes us more concerned about Ozempic 2025 sales, than Wegovy. We are now 8% below the mid-point of 2025 guidance on sales & EBIT. We are 40% below consensus by 2030 on Ozempic sales, which could translate to a 16% cut to cons. group EBIT in 2030. We cut our group sales forecasts by 6-10% and EBIT by 7-17% leaving us 12% below cons. sales by 2027. The catalyst path is also unattractive so offers little support for the stock. Our DKK460 PT puts Novo at a 20% PE premium to Sanofi in 2030 & broadly in-line with AZN despite it having less LOE risk. SELL
For access to the full note, please contact Naresh Chouhan ( )
Underlying
Provider
New Street Research
New Street Research

Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.

New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:

  • Pan European Telecom Services and Cable
  • US Telecoms, Cable, Satellite and Towers
  • Global Emerging Market Telecoms
  • Japan Telecoms
  • Asian Internet
  • Pan European Healthcare
  • Global healthcare thematic research

We provide debt research on:

  • Pan European Telecom Services and Cable


Analysts
Dominic Rose

Naresh Chouhan

Other Reports on these Companies
Other Reports from New Street Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch